Dr. Reddy's Semaglutide Batch Fails OOS Test on API Flaw, Shares Sink 4%

An active-ingredient defect has knocked a semaglutide batch out of specification at Dr. Reddy's, rattling investors and raising supply-continuity questions in the fiercely competitive GLP-1 weight-loss market.

ndtv-profit-business · 7/9/2026, 7:01:32 AM · Ask about this →